Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis
Intestinal Research
;
: 183-186, 2016.
Article
in English
| WPRIM
| ID: wpr-168223
ABSTRACT
Tumor necrosis factor-α inhibitors are now considered as standard therapy for patients with severe inflammatory bowel disease who do not respond to corticosteroids, but they carry a definite risk of reactivation of tuberculosis. We present a case in which a patient with inflammatory bowel disease developed a de novo tuberculosis infection after the start of anti-tumor necrosis factor-α treatment despite showing negative results in tuberculosis screening. Although there are many case reports of pleural, lymph nodal and disseminated tuberculosis following infliximab therapy, we present the first case report of rectal tuberculosis following infliximab therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Tuberculosis
/
Ulcer
/
Inflammatory Bowel Diseases
/
Colitis, Ulcerative
/
Mass Screening
/
Tumor Necrosis Factor-alpha
/
Adrenal Cortex Hormones
/
Latent Tuberculosis
/
Infliximab
/
Necrosis
Type of study:
Diagnostic study
/
Prognostic study
/
Screening study
Limits:
Humans
Language:
English
Journal:
Intestinal Research
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS